Cargando…
Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet’s Disease: Eight Consecutive Cases
The long-term efficacy and safety of adalimumab (ADA) for the treatment of intestinal Behcet’s disease (BD) in the clinical setting have not been evaluated previously. This retrospective study evaluated the 52-week efficacy of ADA in BD patients. A total of eight patients who were refractory to conv...
Autores principales: | Tanida, Satoshi, Mizoshita, Tsutomu, Nishie, Hirotada, Ozeki, Keiji, Katano, Takahito, Shimura, Takaya, Kubota, Eiji, Kataoka, Hiromi, Kamiya, Takeshi, Joh, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780498/ https://www.ncbi.nlm.nih.gov/pubmed/26985255 http://dx.doi.org/10.14740/jocmr2477w |
Ejemplares similares
-
Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2015) -
Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016) -
Organizing Pneumonia in a Patient with Quiescent Crohn's Disease
por: Tanida, Satoshi, et al.
Publicado: (2016) -
Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2020) -
Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement
por: Mizoshita, Tsutomu, et al.
Publicado: (2014)